Abstract：Objective To retrospectively analyze the clinical efficacy and adverse effect of FOLFOX-4 regimen(oxaliplatin combined with fluorouracil and leucovorin) and DF regimen(docetaxel combined with fluorouracil) in the first-line treatment of advanced gastric cancer(AGC).Methods Fifty-five patients with AGC were treated with at least 3 cycles of FOLFOX-4 regimen(n=26) or 2 cycles of DF regimen.Results The overall response rate(ORR),disease control rate(DCR),median progression-free survival(mPFS) and median overall survival(mOS) were,respectively,26.9%,73.1%,5.68 months and 13.89 months in FOLFOX-4 regimen treatment group,and 20.7%,69.0%,3.96 months and 12.71 months in DF regimen treatment group,without significant differences between the two groups(P>0.05).The incidence of grade Ⅲ-Ⅳ neutropenia in DF regimen treatment group was significantly higher than that in FOLFOX-4 regimen treatment group(P<0.05).Conclusion Both DF and FOLFOX-4 regimens are effective and tolerable in the treatment of AGC.
2012, Vol. 52 
